Thursday April 18, 2019 21:52

Heathcare Press Release : 16 May 2018

BDMS Bangkok Hospital and Samitivej Hospital, win 8 Global Health and Travel Awards for the third consecutive year Heathcare—16 May 18

For the third consecutive year, Bangkok Hospital and Samitivej Hospital, members of Bangkok Dusit Medical Services (BDMS), won 8 Global Health and Travel Awards (GHT Awards), at the 2018 Asia Pacific Healthcare & Medical Tourism Summit, the leading

Venus Medtech Receives DCP Capital#s Equity Investment to Accelerate Heart Valve Technology Development and International Commercialization Heathcare—16 May 18

HANGZHOU, China--16 May--PRNewswire/InfoQuest

Venus Medtech announced that it has entered into a definitive investment agreement with DCP Capital. The investment will be used by Venus Medtech to accelerate the upgrading and internationalization of existing valve products, support the company to rapidly enter into the clinical research stage for its new mitral/tricuspid valve disease treatment technology, and lay a solid foundation for the company to comprehensively enter the international heart valve market.

Together with a growing economy and an aging population, the incidence of senile calcific aortic valve disease is on the rise and will soon become the main cause of valvular disease in China. At present, surgical procedures for aortic valve replacement (SAVR) are widely used but the risk of surgical trauma is high and the postoperative recovery is slow. Most of the older patients are unable to tolerate such surgery. After 16 years of rapid development, transcatheter aortic valve replacement (TAVR) technology has gradually become the mainstream treatment for aortic valve disease in the world. According to current indications, there are at least 500,000 patients in China who have TAVR indications and the majority of them are not admitted to hospital for treatment. In addition to aortic valve disease, mitral and tricuspid valve diseases are